Yahoo
NasdaqGS - Delayed Quote USD

LENZ Therapeutics, Inc. (LENZ)

5.96 +0.13 (+2.23%)
At close: September 4 at 4:00:01 PM EDT
6.00 +0.04 (+0.67%)
After hours: September 4 at 7:30:03 PM EDT
Trade LENZ on Coinbase
Chart Range Bar
Loading chart for LENZ
  • Previous Close 5.83
  • Open 5.74
  • Bid 4.13 x 200
  • Ask 7.39 x 200
  • Day's Range 5.61 - 5.97
  • 52 Week Range 4.53 - 50.40
  • Volume 488,956
  • Avg. Volume 855,352
  • Market Cap (intraday) 187.265M
  • Beta (5Y Monthly) 1.63
  • PE Ratio (TTM) --
  • EPS (TTM) -4.13
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.00

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

www.lenz-tx.com

152

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LENZ
62.75%
S&P 500 (^GSPC)
12.75%

1-Year Return

LENZ
85.07%
S&P 500 (^GSPC)
18.71%

3-Year Return

LENZ
20.50%
S&P 500 (^GSPC)
70.93%

5-Year Return

LENZ
91.24%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 5.49M
Earnings -31.92M
Profit Margin -581.81%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-40M
-30M
-20M
-10M
0
10M
-2000.0%
-1500.0%
-1000.0%
-500.0%

Analyst Insights

View More

Analyst Price Targets

7.00
24.00 Average
5.96 Current
60.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/12/2026
Analyst Piper Sandler
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 12 -> 7

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.36%

  • Return on Equity (ttm)

    -59.21%

  • Revenue (ttm)

    21.48M

  • Net Income Avi to Common (ttm)

    -126M

  • Diluted EPS (ttm)

    -4.13

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    220M

  • Total Debt/Equity (mrq)

    0.26%

  • Levered Free Cash Flow (ttm)

    -71.25M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More
Mobilize your Website
View Site in Mobile | Classic
Share by: